How Patanjali’s Coronil and Swasari make mockery of medical regulation in India

Damning piece by Leroy Leo and Goutam Das in Mint:

Besides exaggerated claims, Patanjali’s conduct could have fallen short of both legal and ethical boundaries. The company picked speed over scientific rigour, fuelling doubts on the quality of its clinical trials. In its application of clinical trial with the Clinical Trials Registry of India (CTRI), the company declared that its first patient was enrolled on 29 May. The estimated duration of trial mentioned two months but by 23 June, Patanjali was ready with the medicine, its packaging and marketing plans.

At the conference, Ramdev said the medicines would be available in seven days and an app had been readied to order home deliveries. Most of the other trials have a far longer time window—the Dabur study, which involves multiple sites, declared that the estimated duration of trail is eight months.

“Purely from a process point of view, it (the Patanjali claim) makes a mockery of drug regulation in India. I don’t understand what is the point of having the Drugs and Magic Remedies (Objectionable Advertisements) Act, which provides for criminal prosecution,” Dinesh S. Thakur, a public health activist and an expert in drug regulation, said.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: